200
Participants
Start Date
January 18, 2019
Primary Completion Date
April 9, 2023
Study Completion Date
October 17, 2024
Arbidol
Oseltamivir plus Arbidol will be administrated from Days 1-7.
Placebos
Oseltamivir plus placebos will be administrated from Days 1-7.
China-Japan Friendship Hospital, Beijing
University of Oxford
OTHER
Peking University
OTHER
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention
OTHER_GOV
Capital Medical University
OTHER